Table 4 Tumour response, progression and death
Total | C1750 mg/m2 | C1500 mg/m2 | |
|---|---|---|---|
n = 49 | n = 19 | n = 30 | |
Patient status at end of follow-up, n (%) | |||
Alive, without disease progression | 9 (18.4) | 1 (5.3) | 8 (26.7) |
Alive with disease progression | 19 (38.8) | 9 (47.4) | 10 (33.3) |
Death after disease progression | 15 (30.6) | 6 (31.6) | 9 (30.0) |
Death without disease progression | 6 (12.2) | 3 (15.8) | 3 (10.0) |
Non measurable disease, n | 6 | 2 | 4 |
Best overall response, n (%) | n = 43 | n = 17 | n = 26 |
Complete response | 2 (4.7) | 1 (5.9) | 1 (3.9) |
Partial response | 20 (46.5) | 8 (47.1) | 12 (46.2) |
Stable disease | 15 (34.9) | 8 (47.1) | 7 (26.9) |
Progressive disease | 5 (11.6) | 0 (0.0%) | 5 (19.2) |
Died | 1 (2.3) | 0 (0.0%) | 1 (3.9) |
Complete or partial response (%, 95% CI) | 51.2% (35.5, 66.7) | 52.9% (27.8, 77.0) | 50.0% (29.9, 70.0) |
Confirmed response, n (%) | n = 43 | n = 17 | n = 26 |
Complete response | 2 (4.7) | 1 (5.9) | 1 (3.9) |
Partial response | 13 (30.2) | 7 (41.2) | 6 (23.1) |
Stable disease | 8 (18.6) | 2 (11.8) | 6 (23.1) |
Progressive disease | 15 (34.9) | 5 (29.4) | 10 (38.5) |
Died | 5 (11.6) | 2 (11.8) | 3 (11.5) |
Confirmed complete or partial response (%, 95% CI) | 34.9% (21.0, 50.9) | 47.1% (23.0, 72.2) | 26.9% (11.6, 47.8) |